Vascular and Metabolic Implications of Novel Targeted Cancer Therapies: Focus on Kinase Inhibitors.
Novel targeted cancer therapies, especially kinase inhibitors, have revolutionized the treatment of many cancers and have dramatically improved the survival of several types of malignancies. Because kinases not only are important in cancer development and progression, but also play a critical role in the cardiovascular (CV) system and metabolic homeostasis, important CV and metabolic sequelae have been associated with several types of kinase inhibitors. This paper reviews the incidences and highlights potential mechanisms of vascular and metabolic perturbations associated with 3 classes of commonly used kinase inhibitors that target the vascular endothelial growth factor signaling pathway, the ABL kinase, and the phosphoinositide 3-kinase/AKT/mammalian target of rapamycin signaling pathway. We propose preventive, screening, monitoring, and management strategies for CV care of patients treated with these novel agents.
Department of Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, New York, New York.
Weijuan
W
Li
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Kevin
K
Croce
Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
David P
DP
Steensma
Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
David F
DF
McDermott
Cardiovascular Research Foundation and Columbia University, New York, New York. Electronic address: obenyehuda@crf.org.
Ori
O
Ben-Yehuda
Cardiovascular Division, Vanderbilt-Ingram Cancer Center, and Cardio-Oncology Program, Vanderbilt University School of Medicine, Nashville, Tennessee. Electronic address: javid.moslehi@vanderbilt.edu.
Javid
J
Moslehi
D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy / Q000379:methods*; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
D047428:Protein Kinase Inhibitors
cardio-oncology; metabolic toxicity; vascular toxicity